Endocyte Inc., a developer of drugs for ovarian and lung tumors, raised $75 million in its initial public offering after cutting the price twice this week for a total reduction of as much as 60 percent.
52029
Cancer drugmaker Endocyte raises $75 million in IPO
112856
Drug company paying nh $1.2 million
59972
Winthrop Realty Trust public offering priced at $12.25 per share
97337
Cost of diabetes drugs doubles
135657
Pharmaceutical product development raises dividend 20 percent
124135
Gastric cancer drug market to double to nearly $1.5 billion in 2018
108775
Pharmaceutical company sealed
98304
Drug stocks climb;
43073
SolFocus raises $10.75 million in venture capital
72368
Bears mauling this drug maker's shares
98057
Gastrointestinal endoscopes market to reach $2.7 billion in 2017
158277
MicroPhage raises $11 million
175035
Popular slashes dividend by 75 percent to 2 cents
64947
Pharmasset publicly offers $92.8 million in stock
174383
Genomatica achieves two key commercialization milestones
153297
Oxendine returns $120,000 in contributions
647
JetSuite raises $7.0M